Special Report: The 2024 Lab Enforcement Landscape
Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing
Lab leaders should be wary of telemedicine arrangements, certain marketing firms, and unnecessary PGx and CGx testing
It’s a pretty good sign that fraudulent billing of genetic lab testing has become a priority for federal fraud enforcers when it gets its very own “takedown.”
From - Lab Compliance Advisor
In addition to the usual Medicare and Medicaid anti-fraud laws, labs have a new liability risk to contend with…
By Dan Scungio, MT (ASCP), SLS, CQA (ASQ) bio
Sometimes when I am talking about lab safety and the topic turns to ergonomics, I get an unusual reaction from the audience…
From - Lab Compliance Advisor
For the past five years, the DOJ has followed an enforcement policy designed to hold directors, officers and other top…
From - Lab Compliance Advisor
After a recent dip, OIG enforcement activity has seemingly rebounded, at least in terms of total recoveries. That's the…
From - Lab Compliance Advisor
Fraudulent utilization and billing of urine drug screening first became a priority for federal enforcers since the…